Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.

NCT01073865 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01073865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01073865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 26, 2010
Completion date
November 20, 2017
Enrollment
222 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer